Gene: GALNT14
Official Full Name: polypeptide N-acetylgalactosaminyltransferase 14provided by HGNC
Gene Summary: This gene encodes a Golgi protein which is a member of the polypeptide N-acetylgalactosaminyltransferase (ppGalNAc-Ts) protein family. These enzymes catalyze the transfer of N-acetyl-D-galactosamine (GalNAc) to the hydroxyl groups on serines and threonines in target peptides. The encoded protein has been shown to transfer GalNAc to large proteins like mucins. Alterations in this gene may play a role in cancer progression and response to chemotherapy. [provided by RefSeq, Jun 2016]
Catalog Number | Product Name | Species | Gene | Passage ratio | Mycoplasma testing | Price |
---|---|---|---|---|---|---|
KO17478 | GALNT14 Knockout cell line (HCT 116) | Human | GALNT14 | 1:2~1:4 | Negative | Online Inquiry |
KO17479 | GALNT14 Knockout cell line (HEK293) | Human | GALNT14 | 1:3~1:6 | Negative | Online Inquiry |
KO17480 | GALNT14 Knockout cell line (A549) | Human | GALNT14 | 1:3~1:4 | Negative | Online Inquiry |
GALNT14 Gene Knockout Cell Lines are specifically engineered cellular models that have had the GALNT14 gene completely inactivated. This gene encodes an enzyme responsible for the transfer of N-acetylgalactosamine (GalNAc) to serine or threonine residues on glycoproteins. The knockout of GALNT14 enables researchers to explore the functional implications of this enzyme in various biological processes, including glycosylation pathways, cell signaling, and cancer metastasis.
The key functions of GALNT14 Gene Knockout Cell Lines lie in their ability to simulate and study the downstream effects of altered glycosylation. By disrupting the normal expression of GALNT14, these cell lines provide a unique opportunity to observe changes in cell adhesion, migration, and proliferation, facilitating a deeper understanding of the role of glycosylation in disease states. Researchers can utilize these models to investigate the molecular mechanisms associated with oncogenesis, autoimmune diseases, and more.
The scientific importance of these cell lines extends to both basic research and clinical applications. They serve as invaluable tools for drug discovery, biomarker identification, and therapeutic target validation, particularly in the context of glycan-related pathologies. Compared to traditional wild-type cell lines, GALNT14 knockout cells present a distinct advantage by allowing for the dissection of the contributions of glycosylation to disease phenotypes, thereby accelerating the path toward novel therapeutic interventions.
For researchers, clinicians, and biopharmaceutical companies, the value of GALNT14 Gene Knockout Cell Lines is underscored by their potential to unravel complex biological questions and facilitate innovative solutions. These cell lines empower users with the capability to produce data-rich insights while leveraging the specificity of gene editing technologies.
With extensive expertise in genetic engineering and cell line development, our company is dedicated to providing high-quality biological products that drive forward research and clinical breakthroughs. Our commitment to scientific advancement and customer support ensures that our offerings meet the evolving needs of the scientific community.
Please note that all services are for research use only. Not intended for any clinical use.
If your question is not addressed through these resources, you can fill out the online form below and we will answer your question as soon as possible.
There is no product in your cart. |
CD Biosynsis is a leading customer-focused biotechnology company dedicated to providing high-quality products, comprehensive service packages, and tailored solutions to support and facilitate the applications of synthetic biology in a wide range of areas.